−4.64USD
−135.89 MUSD
17.45 MUSD
29.00 M
About Tarsus Pharmaceuticals, Inc.
Sector
CEO
Bobak Azamian
Headquarters
Irvine
Website
Employees (FY)
244
Founded
2017
ISIN
US87650L1035
FIGI
BBG00RB9BNQ7
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TARS is 33.01 USD — it has increased by 0.49% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tarsus Pharmaceuticals, Inc. stocks are traded under the ticker TARS.
Tarsus Pharmaceuticals, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
TARS stock is 4.53% volatile and has beta coefficient of 1.72. Check out the list of the most volatile stocks — is Tarsus Pharmaceuticals, Inc. there?
One year price forecast for Tarsus Pharmaceuticals, Inc. has a max estimate of 65.00 USD and a min estimate of 30.00 USD.
TARS earnings for the last quarter are −1.28 USD per share, whereas the estimation was −1.35 USD resulting in a 5.22% surprise. The estimated earnings for the next quarter are −1.37 USD per share. See more details about Tarsus Pharmaceuticals, Inc. earnings.
Tarsus Pharmaceuticals, Inc. revenue for the last quarter amounts to 1.87 M USD despite the estimated figure of 399.56 K USD. In the next quarter revenue is expected to reach 5.47 M USD.
Yes, you can track Tarsus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TARS stock has fallen by 13.65% compared to the previous week, the month change is a 4.23% rise, over the last year Tarsus Pharmaceuticals, Inc. has showed a 139.38% increase.
TARS net income for the last quarter is −41.90 M USD, while the quarter before that showed −39.15 M USD of net income which accounts for −7.03% change. Track more Tarsus Pharmaceuticals, Inc. financial stats to get the full picture.
Today Tarsus Pharmaceuticals, Inc. has the market capitalization of 1.23 B, it has decreased by 1.04% over the last week.
No, TARS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TARS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tarsus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 244.00 employees. See our rating of the largest employees — is Tarsus Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tarsus Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tarsus Pharmaceuticals, Inc. stock shows the buy signal. See more of Tarsus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Tarsus Pharmaceuticals, Inc. future price: according to them, TARS price has a max estimate of 65.00 USD and a min estimate of 30.00 USD. Read a more detailed Tarsus Pharmaceuticals, Inc. forecast: see what analysts think of Tarsus Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Tarsus Pharmaceuticals, Inc. EBITDA is −141.87 M USD, and current EBITDA margin is −815.50%. See more stats in Tarsus Pharmaceuticals, Inc. financial statements.